Search This Blog

Monday, March 8, 2021

Mnemonic for improving short-term memory found to also aid longer term memory

 A team of researchers from the Netherlands, Austria and Germany has found that a well-known mnemonic device used to improve short-term memory also improves longer-term memory. In their paper published in the journal Science Advances the group describes testing memory in both memory athletes and a control group.

A common mnemonic  used to help people memorize a lot of information in a short amount of time involves imagining walking a familiar path and assigning items to various milestones along the way. A person might assign a bottle of milk to the front step, for example, a bag of seeds to the rose garden just next to the path on the way to a sidewalk and a bag of a certain kind of nuts, just next to a tree in the yard, if they wanted to memorize their grocery list. In this new effort, the researchers have found that using such a mnemonic device can also help to remember things for a longer period of time—such as four months.

To learn more about the mnemonic device, the researchers enlisted the assistance of 17 of the world's top-ranked memory athletes. Each was asked to memorize a list of items and then the results of their efforts were compared with a  based on intelligence, handedness, gender and age. The researchers then recruited 50 volunteers who were not memory athletes to help with their study. The group was divided into three smaller groups that underwent different levels of training to use the mnemonic device—some were given six weeks of training, others a shorter length of training and the third group received no training at all.

The researchers also took MRI scans of the brains of several members from each group before and after their training and again four months later. Each of the volunteers, including the memory athletes, then attempted to memorize a list of 50 words. As expected, the memory athletes remembered all the words, while the group that received six weeks of training memorized on average 30; those with no training remembered approximately 27.

In the MRI scans, the researchers found less activity in the parts of the prefrontal cortex involved in memory retention in the  athletes, suggesting it was easier for them to memorize the list. The researchers also found that the non-experts were better able to recall the same list of words four months later compared to the group that received no .


Explore further

Memorization tool bulks up brain's internal connections, scientists say

More information: I. C. Wagner et al. Durable memories and efficient neural coding through mnemonic training using the method of loci, Science Advances (2021). DOI: 10.1126/sciadv.abc7606
https://medicalxpress.com/news/2021-03-mnemonic-device-short-term-memory-longer.html

NIH enrolls for trial of Bristol/Pfizer blood clotting treatment for COVID

 The National Institutes of Health has launched the last of three Phase 3 clinical trials to evaluate the safety and effectiveness of blood thinners to prevent life-threatening blood clots in adults diagnosed with COVID-19. The first patient in the trial was enrolled on February 15.  

Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, the trial explores the use of Eliquis® (apixaban 2.5 mg), a blood thinner, or anticoagulant, donated by Bristol Myers Squibb/Pfizer, in patients who have been discharged from the hospital following a diagnosis of moderate-to-severe COVID-19, the disease caused by SARS-CoV-2.    

The ACTIV-4 Convalescent trial is the third of the ACTIV-4 Antithrombotics master protocol for adaptive trials. The other two – one focused on hospitalized COVID-19 patients and the other on patients with COVID-19 who have not been hospitalized – are already underway. The trials are being conducted at more than 100 sites around the world. These trials are overseen by the National Heart, Lung, and Blood Institute (NHLBI), part of the NIH.

Early in the coronavirus pandemic, researchers noticed that many patients who died from COVID-19 had formed blood clots throughout their bodies, including in their smallest blood vessels. This unusual clotting, one of many life-threatening effects of the disease, has caused multiple health complications, from organ damage to heart attack, stroke, and pulmonary embolism.   

 The ACTIV-4 trials will answer critical questions about the proper use of blood thinners or anticoagulants – called antithrombotics – in the treatment of patients with COVID-19, particularly those who suffer from life-threatening blood clots.      

 Recruiting at sites with a significant COVID-19 burden, ACTIV-4 Convalescent is a randomized and placebo-controlled trial.  Researchers will assess if, within 45 days of being hospitalized, patients develop any thrombotic complication – heart attack, stroke, blood clots in major veins and arteries, deep vein and pulmonary thrombosis, or death.      

Trial planning and development work is being done through a collaborative effort with a number of institutions, including Duke University, Durham, North Carolina, University of Pittsburgh; University of Illinois at Chicago; Brigham and Women’s Hospital, Boston; the Medical College of Wisconsin; the University of California, San Francisco; and the University of Ottawa and the Ottawa Hospital Research Institute.

 COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis https://clinicaltrials.gov/ct2/show/NCT04650087   

https://www.nih.gov/news-events/news-releases/statement-nih-starting-enrollment-third-trial-blood-clotting-treatments-covid-19

Too late to buy Ocugen?

 Shares in Ocugen (NASDAQ:OCGN), a Malvern, Penn., biopharmaceutical company, were below $0.30 a share as recently as Dec. 15, and now, they're just above $8 a share. That's after climbing to $10 a share earlier this week. Over the past three months, the company's shares have risen more than 2,500%.

What's behind all of this investor enthusiasm? It isn't the company's balance sheet, at least not yet. Ocugen is a clinical-stage company whose early-stage gene therapies are aimed at preventing or suppressing inherited eye diseases that cause blindness.

Its pipeline includes just three therapies, led by OCU400, which has four U.S. Food and Drug Administration (FDA) orphan drug designations with the potential to treat more than 150 gene mutations of retinitis pigmentosa, a disease that causes a loss of cells in the retina and can lead to blindness.

Looking at the financials

The company reported no revenue for the third quarter and, so far, has only $42,600 in revenue for the year. Through nine months, the company shows a net loss of $18 million, which is an improvement at least over the $32.6 million it lost in the first nine months of 2019.

What has investors excited is Ocugen's deal with India's Bharat Biotech to bring that company's COVID-19 vaccine, Covaxin, to the U.S. market. Ocugen, for its part, is taking the vaccine through all the levels of U.S. regulatory approval, in return for 45% of the profits derived from the vaccine.

On March 3, Ocugen announced preliminary positive data in a phase 3 trial for Covaxin, with the vaccine showing 81% effectiveness in fighting COVID-19. The vaccine has already been given emergency use approval in India, and the early signs on its phase 3 trial show it might have a good chance to be approved for use in the U.S.

The vaccine is inactivated, made up of dead coronavirus. When injected into the body, that dead coronavirus is designed to stimulate an antibody response, making the person be able to ward off an actual coronavirus infection.

OCGN Chart

OCGN DATA BY YCHARTS

Coming late to the party

If approved, Covaxin would be the fourth COVID-19 vaccine approved in the U.S., behind the Pfizer-BioNTechModerna, and Johnson & Johnson vaccines. The question is, how well would the vaccine be adopted here?

One big problem for Covaxin is that it seems to have few advantages over already approved vaccines. Like the Pfizer-BioNTech and Moderna vaccines, Covaxin would be given in two doses, weeks apart, and must be refrigerated. The early results show it being less effective than those vaccines, however, with the Pfizer-BioNTech vaccine demonstrating 95% efficacy, compared with 94% for Moderna's. Covaxin has a better efficacy than Johnson & Johnson's 66%, but that one requires only one shot and does not need to be refrigerated.

There also may be some resistance to approving a vaccine that was controversial when it was approved in India in January, before what many felt was adequate review. On top of that, AstraZeneca also has a vaccine that is in phase 3 trials.

Still, the slow production of vaccines in the United States has hampered the rollout, so another vaccine, particularly one that is already being manufactured in large quantities, may be welcomed by health authorities.

What investors need to be concerned with regarding Ocugen

Covaxin's positive trial is great news for Ocugen, which could use additional revenue. The company has $19.3 billion in cash as of Sept. 30, but more incoming revenue would help it finance its research and development for years to come.

However, the stock's rise over the past three months means whatever benefits Ocugen may get from Covaxin's approval may already be priced in. The slide back from $10 to $8 a share shows that healthcare investors may already be getting wary of how long the bump can last.

Ocugen's therapies ultimately may be very profitable, but with all of them in clinical development or early-stage trials, that's a long way away. The bigger concern is that if Covaxin isn't approved, new investors will be left with a plummeting stock that, based on its fundamentals, is way overpriced.

My advice is to stay away from the stock, at least until its own pipeline begins to pay off.

https://www.fool.com/investing/2021/03/08/should-you-buy-ocugen-stock-in-march/

'Holy Leisure And Hospitality Batman!' Economists React To Feb Jobs Data

 Total nonfarm payroll employment grew by 379,000 jobs in February, the U.S. Bureau of Labor Statistics reported Friday. 

The unemployment rate fell slightly to 6.2%.

Placeholder

Most of February's job gains came from the leisure and hospitality sector, which added 355,000 jobs. A little more than 80% of those jobs were in food services and drinking places.

Retail trade added 41,000 jobs in February and has now added 2 million jobs since May. 

The construction industry saw 61,000 job losses, and employment in the industry is now down 308,000 jobs year-over-year. 

Here's how economists and others reacted to the jobs report on Twitter:

 

 

 

 

 

 

 

 

 

 

 

 

 

Waiving patents alone won't solve COVID-19 vaccine access: developers

 Waiving intellectual property rights will not be enough to resolve COVID-19 vaccine access issues, the developers of the Oxford/Astrazeneca and the Pfizer/BioNTech vaccines said on Monday, ahead of a meeting on the topic at the World Trade Organization this week.

“I don’t think just making IP fully available goes anywhere close to solving the problem...,” said the University of Oxford professor Sarah Gilbert at a World Health Organization virtual press conference.

BioNTech’s Chief Medical Officer Dr Özlem Türeci said at the same briefing: “Patents are one thing, but there are so many other things we have to ensure.”

https://www.reuters.com/article/us-health-coronavirus-who-ip/waiving-patents-alone-wont-solve-covid-19-vaccine-access-developers-idUSKBN2B0269

Brazil study suggests AstraZeneca vaccine effective against Brazil COVID-19 variant

 Preliminary studies suggest the AstraZeneca vaccine will protect against the P1 variant of the coronavirus, Mauricio Zuma, the head of production at Brazil’s Fiocruz biomedical institute said on Monday, confirming a Reuters report on Friday.

The Brazil variant is worrying experts because it is highly contagious and has led several countries to ban travel from the Latin American nation.

https://www.reuters.com/article/us-health-coronavirus-brazil-variant/brazil-study-suggests-astrazeneca-vaccine-is-effective-against-brazil-covid-19-variant-idUSKBN2B026G

Study in Brazil indicates Sinovac vaccine works against P1 variant found there

 Preliminary data from a study in Brazil indicates that the COVID-19 vaccine developed by China’s Sinovac Biotech Ltd is effective against the P1 variant of the virus first discovered in Brazil, a source familiar with the study told Reuters on Monday.

The source, who did not provide data details, said the study had tested the blood of vaccinated people against the Brazilian variant of the virus. Coronavac, as the Sinovac shot is known, is the main vaccine currently being used to inoculate people in Brazil.

https://www.reuters.com/article/us-health-coronavirus-brazil-sinovac-bio/exclusive-study-in-brazil-indicates-sinovac-vaccine-works-against-p1-variant-found-in-brazil-source-idUSKBN2B023U